On August 28, 2024, GSK plc announced that Japan's Ministry of Health granted a SENKU designation for bepirovirsen, an investigational treatment for chronic hepatitis B, expediting its review based on promising trial data. This designation follows a US FDA Fast Track designation earlier this year and highlights the need for innovative treatment options for over 257 million people globally affected by the virus.